By mimicking the natural hormone GLP-1, these medications offer a multifaceted approach to managing blood sugar, reducing appetite, promoting weight loss, and even improving cardiovascular health
It supports a brighter and more even complexion by reducing dullness caused by environmental stress
NIH has released four new SBIR/STTR solicitations (first deadline for all solicitations is September 8, 2026): Parent SBIR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track SBIR awards Parent STTR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track STTR awards SBIR Phase IIB Strategic Breakthrough Award (Clinical Trial Optional) accepts Phase IIB Strategic Breakthrough SBIR awards (for Phase II awardees) SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Clinical Trial Optional) accepts CRP awards (for Phase II awardees) Updated summaries of the research interests, budget waiver topics, and award mechanisms supported by individual Institutes and Centers (ICs) are now housed on the Small Business Funding Considerations and Contacts webpage
E.MartinsL
Your Path to Better Wellness Starts Here Choosing between sermorelin and ipamorelin comes down to your personal goals, health profile, and timeline